Clinical review pending. This article has not yet been reviewed by a licensed clinician, and we would rather say so than print a name that does not exist.
This is general regulatory context for practices. It is not legal or clinical advice, and it names no product.
When a patient asks about a peptide, one of the first questions is what its regulatory status is. The answer shapes informed consent, documentation, and how a practice may talk about the service. This article covers the two statuses a practice meets most often.
An approved medicine
An approved medicine is a specific product from a specific sponsor. Before approval, the sponsor submits its research, and an FDA review team evaluates whether the studies show the drug is safe and effective for its proposed use. FDA also reviews the professional labeling and inspects the facilities where the drug will be made.
Two points follow for a practice:
- Approval is for a product and a use. It does not carry over to a different product that contains a similar molecule, or to a different use.
- "Safe" has a specific meaning. FDA describes it as the benefits appearing to outweigh the known risks. No drug is free of side effects.
A compounded medicine
Compounding is the preparation of a medicine for a patient whose needs an approved product does not meet. FDA gives examples such as a patient with an allergy to a dye, or a child who needs a liquid form.
FDA is direct about status. Compounded medicines are not FDA-approved. FDA does not verify their safety, effectiveness, or quality before they are marketed.
Section 503A of the Federal Food, Drug, and Cosmetic Act sets the conditions that let this kind of preparation proceed without FDA approval before marketing. One of those conditions is a valid patient-specific prescription. In practice that means a named patient, a prescriber's decision for that patient, and no general supply.
Federal law also limits which bulk drug substances may be used. Under section 503A, a bulk substance generally has to comply with a USP or NF monograph if one exists, be a component of an approved drug, or appear on FDA's list for this purpose. That list changes over time. It is one reason a peptide a patient read about may not be available through this path at all.
Section 503B created a separate category, outsourcing facilities, which register with FDA and follow current good manufacturing practice. Our earlier guide, how the 503A and 503B pathways work, covers the operational differences.
What to tell patients
Plain, accurate language protects the patient and the practice.
- Say whether a medicine is approved or compounded, every time.
- If it is compounded, say that it is not FDA-approved and that FDA has not reviewed it for safety, effectiveness, or quality.
- Do not describe a compounded medicine as a version or a copy of an approved one.
- Make no promise of results. Describe what the research shows, and what it does not.
- Document the prescriber's reasoning for that patient.
Where SiriusRx fits
Sirius Peptides, by SiriusRx, gives practices a workspace and managed ordering. SiriusRx works with practices. It does not sell to patients and it does not provide medical care. The prescriber decides every order, for a named patient.
References
- U.S. Food and Drug Administration. "FDA's Drug Review Process: Continued."
- U.S. Food and Drug Administration. "Compounding and the FDA: Questions and Answers."
- U.S. Food and Drug Administration. "Human Drug Compounding Laws."
- U.S. Food and Drug Administration. "Bulk Drug Substances Used in Compounding."
These are public, peer reviewed sources about the underlying physiology. They are not studies of SiriusRx and they do not describe results anyone should expect from us.

